Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMUOFM4)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Diprosone; Diprolene; Diprolene AF; Maxivate; Diproderm; Diprosis; Alphatrex; Psorion; 5593-20-4; Rinderon DP; Betamethasone-17,21-dipropionate; Betamethasone 17,21-dipropionate; Sch-11460; Sch 11460; UNII-826Y60901U; beta-Methasone 17,21-dipropionate; EINECS 227-005-2; S-3440; BRN 3638108; CHEBI:31276; CIWBQSYVNNPZIQ-XYWKZLDCSA-N; S 3440; 826Y60901U; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-dien
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||
